
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : AMV564, a novel first-in-class agent that depletes MDSC and activates T cells, is being investigated in a Phase 1 clinical trial in advanced solid tumors. Phase 1 data support dose and schedule of AMV564 for expansion cohorts in selected solid tumor indi...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 09, 2020

Details : AMV564 translational data for MDSC depletion, Treg control, favorable effector CD8 and CD4 Th1 polarization, along with a cytokine and chemokine milieu conducive to T cell trafficking and antigen presentation is consistent with relief of immune suppressi...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 23, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AMV564,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMV564 showed single-agent activity including one complete response in a heavily pre-treated, checkpoint inhibitor-refractory ovarian cancer patient for whom treatment is ongoing.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : AMV564,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Study of AMV564 in Subjects With Advanced Solid Tumors
Details : AMV564 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 16, 2019

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Details : AMV564 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Myelodysplastic Syndromes.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 04, 2018

Study of AMV564 in Patients With AML
Details : AMV564 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 08, 2017
